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Over the past 50 years, deaths from cardiovascular 
disease, stroke and pneumonia have plummeted as a 
result of new therapies and preventive strategies based 
upon a detailed understanding of the causes and patho-
genesis of these diseases. Over this same period, deaths 
from cancer have changed relatively little. Conse  quently, 
we have now reached a tipping point in history at which 
deaths from cancer will soon surpass those from 
cardiovascular disease. In this regard, breast cancer holds 
the dubious honor of having become the leading cause of 
cancer mortality among women worldwide.
Th   e enormous commitment of resources to research on 
breast cancer, and the dedication of the thousands of 
researchers focused on this problem, is predicated on the 
belief that the prevention, detection and cure of this 
disease will ultimately depend upon a greater under-
standing of the biology of breast cancer than we hold 
today. Equally important, however, is the recognition that 
translating the fruits of basic research to the clinic is an 
extraordinarily challenging task that requires intellectual 
cooperation amongst individuals spanning a broad range 
of expertise and understanding.
For this reason, success in translational research 
requires the conﬂ   uence and engagement of multiple 
disci  plines. Accordingly, the cell biologist, the epidemio-
logist, the molecular biologist, the pathologist, the 
radiologist, the molecular geneticist and the clinical 
researcher have all become inextricably linked in their 
shared quest for progress towards reducing breast cancer 
mortality. Achieving this goal challenges each of these 
specialists to assemble and integrate knowledge from 
diverse ﬁ  elds with which they are relatively unfamiliar.
It was to address precisely this need that Breast Cancer 
Research was launched 12 years ago. Guided by an 
editorial board possessing a wide perspective of specialist 
ﬁ  elds, and supported by scientists actively engaged in the 
laboratory and clinic, Breast Cancer Research has aimed - in 
the words of its founding Editor-in-Chief Sir Bruce 
Ponder - ‘to integrate and interpret biologically based 
research across the whole spectrum relevant to breast 
cancer, to make it accessible to the breast cancer 
community, and to keep in view the goal, however 
distant, of practical application.’
It is with this goal in mind that we present the accom-
panying special review series. With reviews spanning 
breast cancer susceptibility, the molecular genetics and 
cell biology of breast cancer development and progres-
sion, and the validation of new cellular biomarkers for 
clinical trials, this collection reﬂ   ects the focus and 
commitment of Breast Cancer Research to report on all 
areas of biology and medicine relevant to breast cancer.
In our ﬁ  rst review, Boyd and colleagues [1] address a 
fascinating aspect of breast cancer susceptibility as they 
summarize current understanding and future prospects 
regarding the relationship between mammographic 
density and breast cancer risk. Over the past decade, 
mammographic density has emerged as a major risk 
factor for breast cancer, with odds ratios generally in the 
range of 3.5 to 4.5. Indeed, among endocrine, repro-
ductive and familial risks of breast cancer, only age, 
gender, and BRCA1 and BRCA2 carrier status are asso-
ciated with larger relative risks of breast cancer than 
mammographic density. Moreover, since high mammo-
graphic density is common in the population, if the 
association with breast cancer risk is causal, the propor-
tion of the disease attributable to this risk factor is likely 
to be substantial. Intriguingly, age, parity and menopausal 
status account for only a small proportion of the observed 
variation in mammographic density in the population; in 
contrast, twin studies suggest that much of the residual 
variation in mammographic density is the result of 
heritable - presumably polygenic - factors. In light of the 
strong association between mammographic density and 
breast cancer risk, the genetic factors that inﬂ  uence 
mammographic density may represent a treasure trove of 
currently unappreciated genes and pathways that contri-
bute to breast cancer incidence. As such, the identi  ﬁ  -
cation of factors that inﬂ  uence mammographic density 
may lead to a greater understanding of the causes of 
breast cancer as well as new approaches to preventing 
this disease. In their review, Boyd and colleagues survey 
critical aspects of the biological underpinnings of  © 2010 BioMed Central Ltd
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for mammographic screening, individual risk prediction, 
and breast cancer prevention.
In our second review, Arteaga and colleagues [2] 
address the role of mutations in the phosphatidylinositol 
3-kinase (PI3K) pathway in breast cancer progression 
and response to therapy. PI3K serves as a major signaling 
hub downstream of HER2/neu and other receptor 
tyrosine kinases and mutations in the genes constituting 
this pathway occur in >70% of breast cancers, making it 
the most frequently mutated pathway in this disease. 
Moreover, PI3K pathway activation is now recognized as 
an important molecular determinant of resistance to 
anti-estrogen therapies in estrogen receptor-positive 
breast cancers, as well as resistance to HER2/neu-targeted 
therapies in HER2/neu-ampliﬁ  ed breast cancers. Arteaga 
and colleagues review alterations in the PI3K pathway in 
breast cancer, their association with thera  peutic resistance, 
and the state of clinical development of PI3K pathway 
inhibitors. In doing so, they describe an exemplary model 
for the integration and translation of funda  mental 
molecular genetics research to clinical oncology.
Next, Davidson, Oesterreich and colleagues [3] report 
on recent developments in epigenetics and breast cancer, 
an area that has witnessed an explosion of new know-
ledge. Th  eir review emphasizes advances in our under-
standing of histone methylation and demethylation as an 
example of the remarkable progress that has been made 
in recent years towards a basic understanding of how 
various epigenetic changes, such as DNA methylation, 
histone modiﬁ  cation, microRNA expression, and higher 
order chromatin structure, aﬀ  ect gene expression. Th  eir 
review focuses on exciting and rapidly evolving areas 
within epigenetics research, with an emphasis on oppor-
tunities for clinical application, including its promise for 
prognosis, prediction, and therapeutic intervention.
Turning to cell biology, Ford and colleagues [4] examine 
the complexities and nuance of the so-called epithelial-
to-mesenchymal transition (EMT) in breast cancer. Th  e 
EMT is a critical developmental program of cellular 
behavior that has recently come center stage in attempts 
to understand the aggressive behavior of human breast 
cancers. Th   e ability of some breast cancer cells to acquire 
a mesenchymal-like phenotype is strongly associated 
with a host of properties associated with tumor progres-
sion, including increased motility, invasion, anoikis 
resistance, cancer stem cell characteristics and thera-
peutic resistance. Th   is transition appears to be reversible 
with a plasticity that may explain the remarkable ability 
of breast cancer cells to disseminate and adapt to new 
environments. Th   eir review addresses the molecules and 
pathways that mediate EMT in breast cancer, the impact 
of EMT on breast cancer behavior, and the implications 
of this new-found knowledge for breast cancer therapy.
In our ﬁ  fth review, Polyak and associates [5] address 
those factors outside of cancer cells that so profoundly 
aﬀ   ect their behavior. Beginning with the prophetic 
assessment that ‘tumors are wounds that do not heal’ [6], 
the tumor microenvironment is now widely recognized as 
a critical determinant of, and participant in, breast cancer 
progression and the response to anti-neoplastic therapy. 
Consequently, there is enormous interest in develop  ing 
new therapies that target the microenviron  ment with a 
particular aim towards aﬀ  ecting the course of invasion and 
metastatic progression. Th  eir review summarizes recent 
advances in our understanding of the breast cancer 
microenvironment, as well as the challenges of translating 
this knowledge into clinical practice.
Finally, Pantel and colleagues [7] describe recent 
advances pertaining to the biology and clinical relevance 
of circulating tumor cells (CTCs). Th   e detection of CTCs 
in peripheral blood and disseminated tumor cells (DTCs) 
in the bone marrow of breast cancer patients has become 
an extremely active area of translational research with 
more than 200 clinical trials incorporating CTC counts 
as a biomarker in patients with various types of solid 
tumors. As the authors of this review highlight, breast 
cancer has played perhaps the most prominent role in 
elucidating the biology and meaning of CTCs in cancer 
patients. While the clinical relevance of DTCs is well-
established, the biology and relevance of CTCs is at 
present much less clear. Pantel and colleagues summarize 
key ﬁ  ndings with regard to current technologies for CTC 
detection, the biology of CTCs, the relationship between 
CTCs in the bloodstream and DTCs in the bone marrow, 
the clinical relevance of CTCs, and their potential utility 
as predictors of response to therapy. Th  ese advances in 
understanding pave the way for what could be a 
promising new test in the arsenal of clinical oncologists.
When taken together with the highly referenced recent 
research publications in Breast Cancer Research, whose 
abstracts are also included in this issue, we anticipate that 
this series of reviews will both intrigue and enlighten. In 
doing so, we hope to have succeeded in presenting these 
recent advances in a manner that is accessible, accurate, 
and engaging for the entire breast cancer community.
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